[Movalis in osteoarthritis (results of Russian research)].

Abstract

AIM:

Response and tolerance study of a novel nonspecific antiinflammatory drug meloxikam (movalis) in patients with osteoarthrosis (OA).

MATERIALS AND METHODS:

630 OA patients entered a multicenter trial in 29 hospitals. Movalis was given in a dose 7.5 mg or 15 mg (groups 1 and 2, respectively). In poor response the dose 7.5 mg was raised to 15 mg. The course of treatment took 2-4 weeks. The effect was assessed in scores by changes in the complaints.

RESULTS:

Movalis has a significant antiinflammatory and analgetic effect, improved joint function, diminished severity of arthralgia and synovitis. Side effects were occasional.

CONCLUSION:

Movalis introduction in wide rheumatological practice will raise effectiveness of OA treatment and reduce the risk of side effects.

• Authors: E S Tsvetkova
• Journal: Terapevticheskii arkhiv (Ter Arkh) Vol. 71 Issue 11 Pg. 48-50 ( 1999) ISSN: 0040-3660 [Print] Russia (Federation)
• Vernacular Title: Movalis pri osteoartrite (dannye rossiĭskogo issledovaniia).
• PMID: 10626336 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Isoenzymes
• Thiazines
• Thiazoles
• Meloxicam

Topics

• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Arthralgia (drug therapy, etiology)
• Female
• Humans
• Isoenzymes (antagonists & inhibitors)
• Male
• Meloxicam
• Osteoarthritis (complications, drug therapy)
• Pain Measurement
• Russia
• Safety
• Severity of Illness Index
• Thiazines (therapeutic use)
• Thiazoles (therapeutic use)
• Treatment Outcome